220 related articles for article (PubMed ID: 19195498)
21. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.
van Himbergen TM; Matthan NR; Resteghini NA; Otokozawa S; Ai M; Stein EA; Jones PH; Schaefer EJ
J Lipid Res; 2009 Apr; 50(4):730-9. PubMed ID: 19043140
[TBL] [Abstract][Full Text] [Related]
22. Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.
Brunetti ND; Maulucci G; Casavecchia GP; Distaso C; De Gennaro L; Pellegrino PL; Di Biase M
J Interv Cardiol; 2007 Dec; 20(6):481-7. PubMed ID: 18042053
[TBL] [Abstract][Full Text] [Related]
23. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
24. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
Middleton A; Binbrek AS; Fonseca FA; Wilpshaar W; Watkins C; Strandberg TE
Curr Med Res Opin; 2006 Jun; 22(6):1181-91. PubMed ID: 16846551
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
Leiter LA; Rosenson RS; Stein E; Reckless JP; Schulte KL; Schleman M; Miller P; Palmer M; Sosef F;
Atherosclerosis; 2007 Oct; 194(2):e154-64. PubMed ID: 17229426
[TBL] [Abstract][Full Text] [Related]
26. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.
Otokozawa S; Ai M; Van Himbergen T; Asztalos BF; Tanaka A; Stein EA; Jones PH; Schaefer EJ
Atherosclerosis; 2009 Jul; 205(1):197-201. PubMed ID: 19200542
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
Bays HE; Averna M; Majul C; Muller-Wieland D; De Pellegrin A; Giezek H; Lee R; Lowe RS; Brudi P; Triscari J; Farnier M
Am J Cardiol; 2013 Dec; 112(12):1885-95. PubMed ID: 24063830
[TBL] [Abstract][Full Text] [Related]
28. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
[TBL] [Abstract][Full Text] [Related]
29. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.
Bullano MF; Kamat S; Wertz DA; Borok GM; Gandhi SK; McDonough KL; Willey VJ
Am J Health Syst Pharm; 2007 Feb; 64(3):276-84. PubMed ID: 17244877
[TBL] [Abstract][Full Text] [Related]
31. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Hong YJ; Jeong MH; Hachinohe D; Ahmed K; Choi YH; Cho SH; Hwang SH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
Circ J; 2011; 75(2):398-406. PubMed ID: 21157106
[TBL] [Abstract][Full Text] [Related]
32. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
33. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
34. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
[TBL] [Abstract][Full Text] [Related]
35. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
Pitt B; Loscalzo J; Monyak J; Miller E; Raichlen J
Am J Cardiol; 2012 May; 109(9):1239-46. PubMed ID: 22360820
[TBL] [Abstract][Full Text] [Related]
36. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
[TBL] [Abstract][Full Text] [Related]
37. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Edwards JE; Moore RA
BMC Fam Pract; 2003 Dec; 4():18. PubMed ID: 14969594
[TBL] [Abstract][Full Text] [Related]
38. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
Egede R; Jensen LO; Hansen HS; Antonsen L; Hansen KN; Junker A; Thayssen P
Int J Cardiol; 2012 Jul; 158(3):376-9. PubMed ID: 21349594
[TBL] [Abstract][Full Text] [Related]
39. [Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)].
Danchin N; Chadarevian R; Gayet JL; Licour M; Valensi P
Ann Cardiol Angeiol (Paris); 2007 Apr; 56(2):82-7. PubMed ID: 17484092
[TBL] [Abstract][Full Text] [Related]
40. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
